**Core tip:** hepatitis C virus (HCV) infection is associated with increased rates of glucose abnormalities, including diabetes mellitus and insulin resistance. The presence of glucose abnormalities in HCV infected patients, including diabetes mellitus and insulin resistance, is associated with negative liver-related outcomes (*i.e*., severe liver fibrosis, decreased response to antivirals, and increased occurrence of hepatocellular carcinoma).

INTRODUCTION
============

Hepatitis C virus (HCV) infection is a major health problem. The World Health Organization (WHO) estimates that at least 150-170 million people, approximately 3% of the world\'s population, are chronically infected. These patients are known to be at risk of liver related complications, *i.e*., cirrhosis and hepatocellular carcinoma (HCC), with an estimated liver-related mortality of 350000 people/year. The total risks of morbidity and mortality are underestimated, because they do not take into account extrahepatic consequences of HCV infection. Numerous extrahepatic manifestations have been reported, suggesting that HCV is more a systemic disease than just a liver disorder. In large prospective cohort studies, up to two-thirds of patients with HCV infection experienced extra-hepatic manifestations\[[@B1]\]. The majority of available data concern HCV-related autoimmune and/or lymphoproliferative disorders, from benign mixed cryoglobulinemia to frank lymphomas, which is consistent with HCV lymphotropism\[[@B2]\]. More recently, other HCV-associated disorders have been reported including cardiovascular, renal, central nervous system and metabolic diseases\[[@B3]\]. Among the latter, some studies assessed the risk of diabetes mellitus (DM) or insulin resistance (IR) while others evaluated the impact of DM/IR on the main liver-related HCV infection outcomes (*i.e*., liver fibrosis, cirrhosis, HCC). However, the results appear to be conflicting, with great heterogeneity between studies.

In the present study, based on a literature data review, we aimed to analyse: (1) the risk of glucose abnormalities (GA) in HCV-infected patients; and (2) the impact of GA on the main liver-related HCV outcomes, *i.e*., liver fibrosis, response to interferon alfa-based treatment, and HCC.

MATERIALS AND METHODS
=====================

We conducted a PubMed search and selected all studies found with the key words \"HCV\" or \"hepatitis C virus\" and \"diabetes\" or \"insulin resistance\". We included only comparative studies written in English or in French, published from January 2000 to April 2015. We selected surveys that had evaluated the risk of Type 2 DM or IR in HCV-infected patients compared with healthy controls or with patients with hepatitis B virus (HBV) infection. The definition of DM was usually based on a fasting plasma glucose \> 1.26 g/L, or a history of diabetes mellitus, or use of oral antidiabetic agents or insulin. The definition of IR was based on the Homeostasis Model Assessment for Insulin Resistance (HOMA-IR) according to the formula: HOMA-IR = fasting glucose (mmol/L) × fasting insulin (mIU/L)/22.5. We also included studies that assessed the association between the presence of glucose abnormalities (DM or IR) and the main HCV infection outcomes (*i.e*., liver fibrosis, cirrhosis, response to antiviral treatment, HCC). Conversely, studies that evaluated the impact of antiviral treatment on glucose abnormalities were included. We excluded studies with patients infected with the HBV or human immunodeficiency virus, and those for whom the entire manuscript was not available.

RESULTS
=======

Is HCV infection associated with an increased prevalence of glucose abnormalities?
----------------------------------------------------------------------------------

We included two types of studies: (1) those that assessed the HCV prevalence in diabetic patients compared with non-diabetics; and (2) studies that assessed the prevalence of DM and/or IR in HCV-infected patients compared with controls (healthy volunteers or HBV carriers) (Table [1](#T1){ref-type="table"}).

###### 

Glucose abnormalities and hepatitis C virus infection

  **Ref**.                                                                       **Year**   **Country**     **Study design**              **Patients**                          **Patients number**   **Controls**                          **Controls number**   **Testing for HCV Ab or RNA**   **Endpoint**                             **Statistical methods**   **Association**   **Statistics**
  ------------------------------------------------------------------------------ ---------- --------------- ----------------------------- ------------------------------------- --------------------- ------------------------------------- --------------------- ------------------------------- ---------------------------------------- ------------------------- ----------------- -----------------------------------------------------------------------------
  HCV infection markers in patients with type 2 diabetes mellitus                                                                                                                                                                                                                                                                                                                      
  Sangiorgio et al\[[@B4]\]                                                      2000       Italy           Retrospective                 DM                                    1514                  HV                                    1300                  Ab                              HCV                                      Univariate                Yes               *P* \< 0.0001
  Chen et al\[[@B5]\]                                                            2006       Taiwan          Cross sectional               DM                                    820                   HV                                    905                   Ab                              HCV                                      Univariate adjusted       Yes               OR = 2.87 \[1.51, 5.46\]; *P* \< 0.001
  Huang et al\[[@B6]\]                                                           2007       Taiwan          Cross sectional               DM                                    1237                  HV                                    8595                  RNA                             HCV                                      Univariate                Yes               6.9% *vs* 4.5%; *P* \< 0.001
  Jadoon et al\[[@B7]\]                                                          2010       Pakistan        ND                            DM                                    3000                  HV                                    10000                 Ab                              HCV                                      Univariate                Yes               OR = 3.03 \[2.64, 3.48\]; *P* = 0.001
  Balogun et al\[[@B53]\]                                                        2006       Nigeria         case-control                  DM                                    90                    HV[2](#T1FN2){ref-type="table-fn"}    90                    Ab                              HCV                                      Univariate                No                NS
  Costa et al\[[@B54]\]                                                          2008       Brazil          Case-control                  DM                                    206                   HV                                    206                   RNA                             HCV                                      Multivariate              No                NS
  Glucose abnormalities in HCV infected patients *vs* different control groups                                                                                                                                                                                                                                                                                                         
  *Vs* healthy volunteers                                                                                                                                                                                                                                                                                                                                                              
  Knobler et al\[[@B17]\]                                                        2000       Israel          Case-control                  HCV                                   45                    HV[2](#T1FN2){ref-type="table-fn"}    88                    RNA                             DM                                       Univariate                Yes               33% *vs* 5.6%; *P* \< 0.001
  Mehta et al\[[@B8]\]                                                           2000       United States   Cross sectional               HCV                                   230                   HV                                    9611                  Ab                              DM                                       Multivariate              Yes               OR = 3.77 \[1.8, 7.87\]
  Marzouk et al\[[@B18]\]                                                        2007       Egypt           Cross sectional               HCV                                   190                   HV                                    575                   RNA                             DM                                       Multivariate              Yes               HR = 3.05 \[1.19, 7.81\]
  Shaheen et al\[[@B19]\]                                                        2007       United States   ND                            HCV                                   239                   HV                                    10144                 ND                              IR                                       Univariate adjusted       Yes               OR = 1.68; *P* = 0.02
  Huang et al\[[@B6]\]                                                           2007       Taiwan          Cross sectional               HCV                                   478                   HV[2](#T1FN2){ref-type="table-fn"}    7927                  RNA                             DM                                       Multivariate              Yes               OR = 1.53 \[1.18, 1.98\]; *P* \<0.001
  Huang et al\[[@B21]\]                                                          2008       Taiwan          ND                            HCV                                   683                   HV[2](#T1FN2){ref-type="table-fn"}    515                   RNA                             DM/IGT[1](#T1FN1){ref-type="table-fn"}   Univariate                Yes               OR = 3.51 \[2.7, 4.56\]; *P* \< 0.001
  Park et al\[[@B20]\]                                                           2008       South Korea     Prospective                   HCV[1](#T1FN1){ref-type="table-fn"}   62                    HV[2](#T1FN2){ref-type="table-fn"}    172                   RNA                             IR                                       Univariate                Yes               22.5% *vs* 5.2%; *P* \< 0.001
  Mohamed et al\[[@B22]\]                                                        2009       Egypt           Cross sectional               HCV[1](#T1FN1){ref-type="table-fn"}   38                    HV[2](#T1FN2){ref-type="table-fn"}    12                    RNA                             IR                                       Univariate                Yes               HOMA-IR = 3.98 (normal ALT) and 2.69 (a normal ALT) *vs* 1.92; *P* \< 0.001
  Duseja et al\[[@B23]\]                                                         2009       India           ND                            HCV[1](#T1FN1){ref-type="table-fn"}   85                    HV[2](#T1FN2){ref-type="table-fn"}    25                    RNA                             IR                                       Univariate                Yes               62% *vs* 16%; *P* = 0.0002
  Lonardo et al\[[@B24]\]                                                        2009       Italy           ND                            HCV[1](#T1FN1){ref-type="table-fn"}   97                    HV                                    182                   RNA                             IR                                       Univariate                Yes               *P* \< 0.001
  Huang et al\[[@B25]\]                                                          2009       Taiwan          ND                            HCV[1](#T1FN1){ref-type="table-fn"}   93                    HV                                    144                   Ab                              IR                                       Univariate                Yes               HOMA-IR 2.2 *vs* 1.6; *P* = 0.02
  Mostafa et al\[[@B26]\]                                                        2010       Egypt           ND                            HCV                                   329                   HV                                    173/795               RNA                             DM                                       Univariate adjusted       Yes               OR = 1.35 \[1.06, 1.73\]; *P* = 0.02
  Miyajima et al\[[@B27]\]                                                       2013       Japan           Cross sectional               HCV                                   40                    HV                                    1780/88               RNA                             IR                                       Univariate                Yes               HOMA-IR 3.0 *vs* 1.3; *P* \< 0.001
  Younossi et al\[[@B28]\]                                                       2013       United States   Retrospective                 HCV                                   177                   HV                                    19568                 RNA                             DM and IR                                Multivariate              Yes               OR for DM 2.3 \[1.18, 4.54\] OR for IR 2.06 \[1.19, 3.57\]
  Pothineni et al\[[@B29]\]                                                      2014       United States   Retrospective                 HCV                                   1434                  HV[2](#T1FN2){ref-type="table-fn"}    14799                 RNA                             DM                                       Univariate                Yes               11.2% *vs* 5.1%; *P* \< 0.01
  Dai et al\[[@B30]\]                                                            2013       Taiwan          Retrospective                 HCV                                   160                   HV[2](#T1FN2){ref-type="table-fn"}    480                   RNA                             DM                                       Multivariate              Yes               OR = 1.208 \[1.009, 2.799\]; *P* = 0.004
  Mehta et al\[[@B10]\]                                                          2003       United States   Case-control                  HCV                                   12                    HV[2](#T1FN2){ref-type="table-fn"}    1072                  RNA                             DM                                       Univariate                No                NS
  Stepanova et al\[[@B11]\]                                                      2012       United States   Nationwide survey             HCV                                   791                   HV                                    38715                 RNA                             DM and IR                                Multivariate              No                NS
  Montenegro et al\[[@B9]\]                                                      2013       Italy           Prospective                   HCV                                   616                   HV                                    1856                  Ab                              DM                                       Univariate adjusted       No                NS
  Ruhl et al\[[@B55]\]                                                           2014       United States   Cross sectional               HCV                                   277                   HV                                    14571                 RNA                             DM                                       Univariate adjusted       No                NS
  *Vs* hepatitis B virus infection                                                                                                                                                                                                                                                                                                                                                     
  Knobler et al\[[@B17]\]                                                        2000       Israel          Case-control                  HCV                                   45                    HBV                                   90                    RNA                             DM                                       Univariate                Yes               33% *vs* 12%; *P* = 0.004
  Ryu et al\[[@B31]\]                                                            2001       South Korea     Prospective                   HCV, F4                               68                    HBV                                   157                   Ab                              DM                                       Univariate                Yes               24% *vs* 10.4%; *P* = 0.001
  Wang et al\[[@B32]\]                                                           2007       Taiwan          Longitudinal                  HCV                                   926                   HBV                                   544                   Ab                              DM                                       Multivariate              Yes               HR = 1.7
  Huang et al\[[@B6]\]                                                           2007       Taiwan          Cross sectional               HCV                                   478                   HBV                                   1363                  RNA                             DM                                       Univariate                Yes               18% *vs* 11.4%; *P* \< 0.001
  Moucari et al\[[@B33]\]                                                        2008       France          Retrospective                 HCV                                   500                   HBV[2](#T1FN2){ref-type="table-fn"}   100                   RNA                             HOMA-IR                                  Univariate                Yes               35% *vs* 5%; *P* \< 0.001
  White et al\[[@B12]\]                                                          2008       United States   Meta-analysis                 HCV                                   34 studies            HBV/ HV                               \-                    Ab/RNA                          DM                                       Meta-analysis             Yes               Adjusted OR for HV 1.68 and for HBV 1.80
  Rouabhia et al\[[@B34]\]                                                       2010       Algeria         Prospective cross sectional   HCV[1](#T1FN1){ref-type="table-fn"}   290                   HBV                                   126                   RNA                             DM                                       Multivariate              Yes               OR = 4.73 \[1.7, 13.2\]; *P* = 0.0029
  Petta et al\[[@B56]\]                                                          2011       Italy           Retrospective                 HCV                                   170                   HBV[2](#T1FN2){ref-type="table-fn"}   170                   RNA                             HOMA-IR and DM                           Univariate                Yes               42.2% *vs* 25.9%, *P* = 0.002 and 8.8% *vs* 3.6%, *P* = 0.04
  Imazeki et al\[[@B57]\]                                                        2008       Japan           Retrospective                 HCV                                   544                   HBV                                   286                   RNA                             DM and IR                                Multivariate              No                NS
  Tanaka et al\[[@B58]\]                                                         2008       Japan           Case-control                  HCV[1](#T1FN1){ref-type="table-fn"}   30                    HBV[2](#T1FN2){ref-type="table-fn"}   30                    RNA                             IR                                       Multivariate              No                NS
  Mavrogiannaki et al\[[@B59]\]                                                  2008       Greece          prospective case control      HCV                                   108                   HBV                                   81                    RNA                             glucose intolerance                      Univariate adjusted       No                NS
  Persico et al\[[@B60]\]                                                        2009       Italy           Retrospective                 HCV                                   726                   HBV                                   126                   Ab                              DM                                       Univariate adjusted       No                NS

HCV infection not treated;

Matched for confounding factors (age and/or gender and/or BMI and/or ALT...). HCV: Hepatitis C virus infection; Ab: Antibody; HV: Healthy volunteers; G1: Genotype 1; SVR: Sustained virological response; HOMA-IR: Homeostasis Model Assessment of Insulin Resistance; IR: Insulin resistance; DM: Diabetes mellitus; FPG: Fasting plasma glucose; IGT: Impaired glucose tolerance \[after oral glucose tolerance test (OGTT)\]; CLD: Chronic liver disease; NAFLD: Non-alcoholic fatty liver disease; NS: Not significant; ND: Not determined.

Six studies evaluated HCV prevalence rates in diabetic patients compared with non-diabetic healthy volunteers. The number of participants ranged from 180 to 13000. Four out of the six studies showed a significant increased prevalence of HCV infection markers \[HCV antibodies (*n* = 3), HCV RNA (*n* = 1)\] in DM patients, with an odds ratio (OR) between 2.87 and 3.03\[[@B4]-[@B7]\]. Of note, only one study used multivariate logic regression analysis, while another adjusted the risk for age, gender, body mass index (BMI) and alanine aminotransferase (ALT) levels. One study showed an increased HCV antibody prevalence rate in DM patients with abnormal ALT levels.

Thirty-two studies evaluated DM and/or IR prevalence rates in HCV patients compared with either healthy volunteers (*n* = 20) or HBV patients (*n* = 12). The size of cohorts ranged from 50 to 39506 subjects. All but four studies assessed DM/IR prevalence in HCV-RNA positive patients. In 10 out of 20 studies that compared HCV patients with healthy volunteers, multivariate or univariate analyses with adjustment for age, gender, BMI, socio-economic status and ethnicity were performed. Thirteen studies evaluated DM prevalence (*n* = 11) or occurrence (*n* = 2), while others (*n* = 9) assessed IR in HCV infected patients. Overall, 16 out of 20 studies found a significant association between the presence of glucose abnormalities (DM/IR) and HCV infection, including 7 out of 10 studies with multivariate or adjusted analyses (OR between 1.2 and 3.77). One study reported a higher risk of DM only in patients older than 40 years\[[@B8]\]. Four studies reported \"negative\" results. Three out these four studies showed a higher risk of DM only in specific populations (*i.e*., HCV patients with increased ALT levels\[[@B9]\], HCV patients older than 55 years with a BMI \> 25 kg/m^2^\[[@B10]\], and a cohort studied between 1988 and 1994, but not in the more recent cohort)\[[@B11]\].

When compared with HBV infected patients, 7 out of 11 studies found a significant association of HCV with DM. In one meta-analysis\[[@B12]\], a positive HCV viremia was associated with an increased risk of DM compared with controls (adjusted OR = 1.68) and with HBV patients (adjusted OR = 1.80).

Are diabetes mellitus or insulin resistance associated with liver fibrosis severity in HCV infected patients?
-------------------------------------------------------------------------------------------------------------

Thirty studies investigated whether DM/IR was associated with liver fibrosis severity in HCV patients (Table [2](#T2){ref-type="table"}). Studies were performed in Asia (Taiwan *n* = 3, Japan *n* = 3, other *n* = 1), Europe (*n* = 13), the United States and Australia (*n* = 5), Saudi Arabia (*n* = 1), Turkey (*n* = 1) and Egypt (*n* = 3). The mean size of the cohorts was 451 patients (min-max range 10 to 3068). The authors searched for an association between liver fibrosis severity and DM (*n* = 9), IR (*n* = 19) or impaired fasting plasma glucose (*n* = 2). All but two studies performed multivariate analyses. Twenty-six out of thirty studies reported a significant association of glucose abnormalities with liver fibrosis severity (OR from 1.28 to 13.72). Three of the four \"negative\" studies were done on small cohorts. There were some differences related to HCV genotypes, but no systematic relationship was found.

###### 

Glucose abnormalities and severe liver fibrosis in hepatitis C virus-infected patients

  **Ref**.                      **Year**   **Country**      **Number of HCV patients**   **Patient profile**         **Glucose abnormality**   **Statistical method**   **Association with severe fibrosis[1](#T2FN1){ref-type="table-fn"}**   **Genotypes**     **Statistics**
  ----------------------------- ---------- ---------------- ---------------------------- --------------------------- ------------------------- ------------------------ ---------------------------------------------------------------------- ----------------- ------------------------------------------
  Konrad et al\[[@B42]\]        2000       Germany          10                           Non DM                      FPG                       Multivariate             Yes                                                                    All               *P* = 0.01
  Sud et al\[[@B61]\]           2004       Australia        170                          \-                          HOMA-IR                   Multivariate             Yes                                                                    All               OR = 1.47 \[1.14, 1.89\]; *P* = 0.003
  Muzzi et al\[[@B62]\]         2005       Switzerland      221                          Non DM                      HOMA-IR                   Multivariate             Yes                                                                    All (except G3)   OR = 1.57 \[1.04, 2.39\]
  D\'souza et al\[[@B63]\]      2005       United Kingdom   59                           \-                          HOMA-IR                   Multivariate             Yes                                                                    All               *P* = 0.001
  Taura et al\[[@B64]\]         2006       Japan            83                           \-                          HOMA-IR                   Multivariate             Yes                                                                    All               OR = 7.32 \[1.59, 33.73\]; *P* = 0.01
  Leandro et al\[[@B65]\]       2006       Italy            3068                         \-                          DM                        Multivariate             Yes                                                                    G1                OR = 4.52 \[1.07, 19.1\]; *P* = 0.011
  Bugianesi et al\[[@B66]\]     2006       Italy            132                          G3 with steatosis           HOMA-IR                   Multivariate             Yes                                                                    G3                OR = 2.98 \[1.13, 7.89\]; *P* = 0.028
  Kita et al\[[@B67]\]          2007       Japan            68                           Post tranfusion hepatitis   DM                        Multivariate             Yes                                                                    All               OR = 8.4 \[2.23, 31.54\]; *P* = 0.002
  Petta et al\[[@B68]\]         2008       Italy            201                          G1                          DM                        Multivariate             Yes                                                                    G1                OR = 2.69 \[1.46, 4.95\]; *P* \< 0.001
  Moucari et al\[[@B33]\]       2008       France           500                          \-                          HOMA-IR                   Multivariate             Yes                                                                    All               OR = 1.8 \[1.16, 2.81\]; *P* = 0.009
  Cua et al\[[@B69]\]           2008       Australia        346                          G1, G3, untreated           IR                        Multivariate             Yes                                                                    G3                OR = 3.15 \[1.56, 6.35\]; *P* = 0.001
  Hsu et al\[[@B70]\]           2009       Taiwan           528                          G1, G2                      FPG                       Multivariate             Yes                                                                    G1                OR = 13.72 \[2.15, 87.7\]; *P* \< 0.05
  Moucari et al\[[@B71]\]       2009       France           226                          G4                          HOMA-IR                   Multivariate             Yes                                                                    G4                OR = 3.86 \[1.859, 8.034\]; *P* \< 0.001
  Persico et al\[[@B60]\]       2009       Italy            726                          \-                          DM                        Multivariate             Yes                                                                    All               *P* \< 0.05
  Hung et al\[[@B14]\]          2011       Taiwan           1470                         \-                          DM                        Univariate               Yes                                                                    All               *P* \< 0.001
  Patel et al\[[@B72]\]         2011       Asia             263                          G2, G3                      HOMA-IR                   Multivariate             Yes                                                                    G2 and G3         OR = 8.42 \[2.1, 34.3\]; *P* = 0.003
  Mohamed et al\[[@B73]\]       2011       Egypt            50                           G4                          HOMA-IR                   Multivariate             Yes                                                                    G4                OR = 3.73; *P* = 0.001
  Miyaaki et al\[[@B74]\]       2011       Japan            171                          \-                          DM                        Multivariate             Yes                                                                    All               OR = 8.739 \[2.85, 26.85\]; *P* = 0.0002
  Conjeevaram et al\[[@B75]\]   2011       United States    341                          G1                          HOMA-IR                   Multivariate             Yes                                                                    G1                OR = 1.28 \[1.07, 1.51\]; *P* = 0.005
  Petta et al\[[@B56]\]         2011       Italy            170                          G1                          HOMA-IR                   Multivariate             Yes                                                                    G1                OR = 2.64 \[1.11, 6.28\]; *P* = 0.02
  Khattab et al\[[@B76]\]       2012       Egypt            107                          G4                          HOMA-IR                   Multivariate             Yes                                                                    G4                OR = 1.87 \[1.09, 8.29\]; *P* = 0.04
  Ziada et al\[[@B77]\]         2012       Egypt            140                          Non DM                      HOMA-IR                   Multivariate             Yes                                                                    All               OR = 1.92 \[0.97, 3.4\]; *P* = 0.049
  Thompson et al\[[@B13]\]      2012       United States    1038                         Non DM                      HOMA-IR                   Multivariate             Yes                                                                    All               OR = 1.6 \[1.1, 2.33\]; *P* = 0.02
  Alfaleh et al\[[@B78]\]       2013       Saudi Arabia     157                          \-                          DM                        Multivariate             Yes                                                                    All (except G4)   OR = 0.37 \[0.148, 0.927\]; *P* = 0.034
  Dokmeci et al\[[@B79]\]       2014       Turkey           104                          \-                          HOMA-IR                   Multivariate             Yes                                                                    All               OR = 3.36 \[1.32, 31.25\]; *P* = 0.021
  Huang et al\[[@B80]\]         2015       Taiwan           1077                         \-                          DM                        Multivariate             Yes                                                                    All               OR = 1.81 \[1.14, 2.65\]; *P* = 0.002
  Fartoux et al\[[@B81]\]       2005       France           141                          Non DM                      HOMA-IR                   Univariate               No                                                                     No                NS
  Elgouhari et al\[[@B82]\]     2008       United States    183                          \-                          DM                        Multivariate             No                                                                     No                NS
  Petta et al\[[@B83]\]         2009       Italy            156                          Non DM                      HOMA-IR                   Multivariate             No                                                                     No                NS
  Rueger et al\[[@B84]\]        2014       Switzerland      1461                         \-                          DM                        Multivariate             No                                                                     No                NS

Severe liver fibrosis: F3 or F4 in Metavir scoring system. HCV: Hepatitis C virus infection; G1: Genotype 1; SVR: Sustained virological response; HOMA-IR: Homeostasis Model Assessment of Insulin Resistance; IR: Insulin resistance; DM: Diabetes mellitus; FPG: Fasting plasma glucose; NS: Not significant.

Do diabetes mellitus and insulin resistance have an impact on the virological response to HCV treatment?
--------------------------------------------------------------------------------------------------------

Twenty-six studies and three meta-analyses investigated whether GA had an impact on the response to interferon alfa-based antiviral treatment (Table [3](#T3){ref-type="table"}). The studies originated from Europe (*n* = 11), Asia (*n* = 4), Egypt (*n* = 4), the United States (*n* = 5), Australia (*n* = 1) and Saudi Arabia (*n* = 1). They included a mean of 503 patients (50 to 5944). Nineteen out of twenty-eight studies showed a significant negative effect of GA in response to interferon alfa-based therapy \[*i.e*., lower sustained viral response (SVR) rates\], including 15 multivariate analyses and 3 meta-analyses. Of note, studies that did not find an impact of GA on SVR rates had some limitations, including small size of cohorts (60-600 patients), only G1 or G4 patients (3 out of 10 studies), and only Italian patients (4 out of 10). Two of them evaluated patients treated with peginterferon/ribavirin and telaprevir. The three meta-analyses found a significant association between IR and the absence of SVR, regardless of the genotype (OR for G1 = 2.2, G2 = 3, G3 = 4.45 and G4 = 6.7, respectively).

###### 

Impact of glucose abnormalities on virological response after interferon alpha based treatment

  **Ref**.                       **Year**   **Country**      **Patients number**                   **Patient profile**   **Association**   **Statistical method**   **Impact on virological response**   **Genotypes**   **Statistics**
  ------------------------------ ---------- ---------------- ------------------------------------- --------------------- ----------------- ------------------------ ------------------------------------ --------------- --------------------------------------------------------------
  D\'souza et al\[[@B63]\]       2005       United Kingdom   59                                                          HOMA-IR           Multivariate             Yes                                  All             OR of SVR: 0.44 \[0.22, 0.88\]; *P* = 0.02
  Tarantino et al\[[@B85]\]      2005       Italy            80                                                          GMI               Univariate               Yes                                  All             40% *vs* 7.5%; *P* = 0.0009
  Romero-Gomez et al\[[@B86]\]   2005       Spain            159                                                         HOMA-IR           Multivariate             Yes                                  All             OR of SVR 0.55 \[0.33, 0.93\]; *P* = 0.012
  Jian Wu et al\[[@B87]\]        2006       China            98                                                          HOMA-IR           Multivariate             Yes                                  All             OR of SVR: 0.17; *P* = 0.015
  Backus et al\[[@B88]\]         2007       United States    5944                                  G1, G2, G3            DM                Multivariates            Yes                                  All and G1      OR = 0.76 \[0.64, 0.71\]; *P* = 0.002
  Conjeevaram et al\[[@B89]\]    2007       United States    401                                   G1                    HOMA-IR           Multivariates            Yes                                  G1              OR = 0.87 \[0.77, 0.99\]; *P* = 0.028
  Elgouhari et al\[[@B82]\]      2008       United States    183                                                         DM                Multivariate             Yes                                  All             OR of SVR 0.22 \[0.07, 0.55\]; *P* = 0.003
  Poustchi et al\[[@B90]\]       2008       Australia        82                                    G2, G3 non DM         HOMA-IR           Multivariate             Yes                                  G2, G3          OR of SVR 0.16 \[0.03, 0.77\]; *P* = 0.02
  Romero-Gomez et al\[[@B91]\]   2008       Spain            1059                                                        FPG               Multivariate             Yes                                  All             OR of SVR 0.56 \[0.34, 0.93\]; *P* \< 0.02
  Moucari et al\[[@B71]\]        2009       France           226                                   G4                    HOMA-IR           Multivariate             Yes                                  \-              OR of SVR: 0.19 \[0.07, 0.51\]; *P* = 0.001
  Dai et al\[[@B92]\]            2009       Taiwan           330                                   G1, G2                HOMA-IR           Multivariate             Yes                                  G1, G2          OR of SVR 0.872 \[0.79, 097\]; *P* = 0.01
  Hung et al\[[@B115]\]          2010       Taiwan           1470                                                        DM                Multivariate             Yes                                  All             OR of SVR 0.69 \[0.5, 0.96\]; *P* = 0.029
  Khattab et al\[[@B93]\]        2010       Egypt            131                                   Non DM, G4            HOMA-IR           Multivariate             Yes                                  G4              OR of SVR 0.07 \[0.01, 0.43\]; *P* = 0.004
  Deltenre et al\[[@B94]\]       2011       France           2732                                  G1-6                  IR                Meta-analysis            Yes                                  All             \-
  Eslam et al\[[@B95]\]          2011                        2129                                  G1-6                  IR                Meta-analysis            Yes                                  All             OR of SVR 0.35 \[0.24, 0.51\]; *P* = 0.0004
  Del Campo et al\[[@B96]\]      2012       Spain            240                                   Non DM                HOMA-IR           Multivariate             Yes                                  G1, G4          OR of SVR 0.44 \[0.17, 0.97\]; *P* = 0.04
  Ziada et al\[[@B77]\]          2012       Egypt            140                                   Non DM                HOMA-IR           Multivariate             Yes                                  All             OR of SVR 0.41 \[0.18, 0.9\]; *P* = 0.003
  Laurito et al\[[@B97]\]        2013       Brazil           2238                                  G1-6                  IR                Meta-analysis            Yes                                  All             OR of SVR 0.41 \[0.3, 0.56\]; *P* = 0.022
  Abd El-Wahab et al\[[@B98]\]   2014       Egypt            392                                   Non DM                HOMA-IR           Multivariate             Yes                                  All             OR of virological response: 0.19 \[0.1, 0.38\]; *P* = 0.0001
  Grasso et al\[[@B99]\]         2009       Italy            90                                    Non DM, G1            HOMA-IR           Multivariate             No                                   G1              NS
  Fattovich et al\[[@B100]\]     2010       Italy            412                                                         HOMA-IR           Multivariate             No                                   No              NS
  Khattab et al\[[@B76]\]        2012       Egypt            107                                   G4                    HOMA-IR           Multivariate             No                                   G4              NS
  Brandman et al\[[@B101]\]      2012       United States    23                                    Non DM                IGT, FGP, SSGP    Univariate               No                                   No              NS
  Aghemo et al\[[@B102]\]        2012       Italy            339                                                         HOMA-IR           Univariate               No                                   No              NS
  Fattovich et al\[[@B100]\]     2012       Italy            124                                   Non DM                HOMA-IR           Multivariate             No                                   No              NS
  Serfaty et al\[[@B103]\]       2012       France           161[1](#T3FN1){ref-type="table-fn"}   G4                    HOMA-IR           Multivariate             No                                   G4              NS
  Alfaleh et al\[[@B78]\]        2013       Saudi Arabia     157                                                         DM                Multivariate             No                                   No              NS
  Younossi et al\[[@B104]\]      2013       United States    578[1](#T3FN1){ref-type="table-fn"}   G1                    HOMA-IR           Univariate adjusted      No                                   G1              NS
  Jung et al\[[@B105]\]          2014       Soutk Korea      60                                                          HOMA-IR           Univariate               No                                   No              NS

Treated with peginterferon/ribavirin telaprevir. HCV: Hepatitis virus infection; G1: Genotype 1; SVR: Sustained virological response; HOMA-IR: Homeostasis Model Assessment of Insulin Resistance; IR: Insulin resistance; IGT: Impaired glucose tolerance; DM: Diabetes mellitus; FPG: Fasting plasma glucose; SSGP: Steady-state plasma glucose; GMI: Glucose metabolism impairment; NS: Not significant; ND: Not determined.

What is the impact of interferon alfa-based treatment on glucose abnormalities?
-------------------------------------------------------------------------------

Twenty studies assessed the impact of interferon-based antiviral treatment on DM/IR, either as an improvement of GA after treatment or as the occurrence of GA after antiviral treatment (Table [4](#T4){ref-type="table"}).

###### 

Glucose abnormalities after interferon alpha based treatment

  **Ref**.                                                   **Year**   **Country**     **Number of HCV patients**   **Patient profile**     **Glucose metabolism parameter**   **Statistical method**                         **Significant association or difference**   **Genotypes**   **Statistics**
  ---------------------------------------------------------- ---------- --------------- ---------------------------- ----------------------- ---------------------------------- ---------------------------------------------- ------------------------------------------- --------------- -------------------------------------------------------------
  Improvement of glucose abnormalities after HCV treatment                                                                                                                                                                                                                                 
  Konrad et al\[[@B42]\]                                     2000       United States   13                                                   FPG and FI                         Univariate                                     Yes                                         All             *P* \< 0.05 and *P* \< 0.01
  Romero-Gomez et al\[[@B86]\]                               2005       Spain           50                                                   HOMA-IR                            Univariate                                     Yes                                         All             In SVR; *P* \< 0.05
  Kawaguchi et al\[[@B106]\]                                 2007       Japan           89                                                   HOMA-IR                            Univariate                                     Yes                                         All             In SVR; *P* \< 0.01
  Chehadeh et al\[[@B107]\]                                  2009       Kuwait          181                          G4                      FPG                                Univariate                                     Yes                                         G4              In SVR; *P* \< 0.001
  Kim et al\[[@B108]\]                                       2009       Korea           28                           G1, G2                  HOMA-IR                            Multivariate                                   Yes                                         G1, G2          In SVR, OR of decreased IR 50 \[3.74, 668.35\]; *P* = 0.003
  Conjeevaram et al\[[@B75]\]                                2011       United States   341                          G1                      HOMA-IR                            Univariate                                     Yes                                         G1              In SVR; *P* \< 0.001
  Khattab et al\[[@B76]\]                                    2012       Egypt           107                          G4, non cirrhotic       HOMA-IR                            Univariate                                     Yes                                         G4              In SVR ; *P* = 0.001
  Thompson et al\[[@B13]\]                                   2012       United States   1038                                                 HOMA-IR                            Multivariate[1](#T4FN1){ref-type="table-fn"}   Yes                                         All             In G1 SVR; *P* = 0.007
  Serfaty et al\[[@B103]\]                                   2012       France          161                          G1, non cirrhotic       HOMA-IR                            Univariate                                     Yes                                         G1              In SVR ; *P* \< 0.05
  Ziada et al\[[@B77]\]                                      2012       Egypt           140                          Non DM, non cirrhotic   HOMA-IR                            Univariate                                     Yes                                         All             *P* = 0.009
  Chan et al\[[@B109]\]                                      2013       Australia       86                           Non DM                  HOMA-IR                            Univariate                                     Yes                                         All             In SVR; *P* = 0.04
  Jung et al\[[@B105]\]                                      2014       South Korea     60                                                   HOMA-IR                            Univariate                                     Yes                                         All             In SVR; *P* = 0.036
  Mello et al\[[@B110]\]                                     2006       Brazil          30                           G1, G3                  HOMA-IR                            Univariate                                     No                                          All             NS
  Kawaguchi et al\[[@B111]\]                                 2009       Japan           72                           Non DM, non cirrhotic   HOMA-IR, SI and ISI                Univariate[1](#T4FN1){ref-type="table-fn"}     No                                          No              HOMA-IR: NS In SVR, SI *P* = 0.002 and ISI *P* = 0.009
  Brandman et al\[[@B101]\]                                  2012       United States   23                           Non cirrhotic           SSGP                               Univariate                                     No                                          No              NS
  Occurrence of glucose abnormalities after HCV treatment                                                                                                                                                                                                                                  
  Simó et al\[[@B112]\]                                      2006       Spain           234                          Non DM                  DM or IGT                          Multivariate[1](#T4FN1){ref-type="table-fn"}   Yes                                         All             In SVR, OR = 0.48 \[0.24, 0.48\]; *P* = 0.04
  Romero-Gomez et al\[[@B91]\]                               2008       Spain           1059                                                 DM or IGT                          Multivariate[1](#T4FN1){ref-type="table-fn"}   Yes                                         All             In SVR, OR = 0.44 \[0.2, 0.97\]; *P* = 0.04
  Arase et al\[[@B113]\]                                     2009       Japan           2842                                                 DM                                 Multivariate[1](#T4FN1){ref-type="table-fn"}   Yes                                         All             In SVR, HR = 0.36 \[0.24; 0.56\]
  Aghemo et al\[[@B102]\]                                    2012       Italy           339                          Non DM                  HOMA-IR                            Multivariate[1](#T4FN1){ref-type="table-fn"}   Yes                                         All             In SVR, OR = 0.36 \[0.18, 0.72\]; *P* = 0.004
  Giordanino et al\[[@B114]\]                                2008       Italy           202                          Non DM                  DM or IGT                          Multivariate[1](#T4FN1){ref-type="table-fn"}   No                                          No              NS

association with SVR. HCV: Hepatitis C virus infection; G1: Genotype 1; SVR: Sustained virological response; HOMA-IR: Homeostasis Model Assessment of Insulin Resistance; IR: Insulin resistance; DM: Diabetes mellitus; FPG: Fasting plasma glucose; FI: Fasting insulin; IGT: Impaired glucose tolerance; ISI: Insulin sensitivity index; SI: Serum insulin; SSGP: Steady-state plasma glucose; NS: Not significant.

Improvement of GA after antiviral treatment was analysed in fifteen surveys that included 13 to 1038 HCV treated patients. Most of these studies performed univariate analyses. A significant decreased prevalence of GA was noted in 12 out of 15 studies. Eleven of these 12 studies reported a significant change of IR only in patients who achieved a SVR. One survey found a significant change of IR after antiviral treatment only in genotype 1 patients\[[@B13]\].

Five studies evaluated the risk of GA occurrence according to antiviral treatment response. They included 202 to 2842 HCV treated patients, and all performed multivariate analyses. Four out of five studies showed a significant association between GA occurrence and the absence of SVR.

Do glucose abnormalities increase the risk of HCC in HCV infected patients?
---------------------------------------------------------------------------

Sixteen studies assessed the association between HCC and DM/IR in HCV infected patients (Table [5](#T5){ref-type="table"}). These studies included from 120 to 5186 HCV patients, both treated and non-treated. Most of them (10/16) included Asian patients, and all but one performed multivariate analyses.

###### 

Glucose abnormalities and hepatocellular carcinoma in hepatitis C virus-infected patients

  **Ref**.                                                                               **Year**   **Country**   **Patient number**   **Patient profile**              **Association**                              **Statistical method**   **Association DM and HCC**            **Statistics**
  -------------------------------------------------------------------------------------- ---------- ------------- -------------------- -------------------------------- -------------------------------------------- ------------------------ ------------------------------------- ------------------------------------------------------------------------
                                                                                                                                                                                                                                                                                    
  Diabetes mellitus/insulin resistance in HCV-related HCC                                                                                                                                                                                                                           
  K-Kutala et al\[[@B15]\]                                                               2014       France        162                  HCC, not treated for HCV         DM and HCC                                   Multivariate             Yes[3](#T5FN3){ref-type="table-fn"}   HR = 3.13 \[1.17, 8.38\]; *P* = 0.022[3](#T5FN3){ref-type="table-fn"}
  Hung et al\[[@B115]\]                                                                  2010       Taiwan        188                  59 HCC; 129 non-HCC              DM and HCC                                   Multivariate             Yes                                   OR = 11.6 \[2.500, 53.800\]; *P* = 0.002
  Hung et al\[[@B115]\]                                                                  2010       Taiwan        188                  59 HCC; 129 non-HCC              HOMA-IR and HCC                              Multivariate             Yes                                   OR = 2.0 \[1.35, 3\]; *P* = 0.001
  Khattab et al\[[@B116]\]                                                               2012       Egypt         294                  147 HCC; 147 non-HCC             HOMA-IR and HCC                              Multivariate             Yes                                   OR = 2.5 \[1.7, 3.69\]; *P* = 0.001
  Mohamed et al\[[@B73]\]                                                                2011       Egypt         100                  50 HCC; 50 non-HCC; 20 non HCV   HOMA-IR and HCC                              Univariate               No                                    NS
  Diabetes mellitus/insulin resistance and development of HCC in HCV-infected patients                                                                                                                                                                                              
  Chen et al\[[@B117]\]                                                                  2008       Taiwan        1095                 \-                               DM and HCC                                   Multivariate             Yes                                   OR = 3.52 \[1.29, 9.24\]
  Veldt et al\[[@B16]\]                                                                  2008       Europe        541                                                   DM and HCC                                   Multivariate             Yes[3](#T5FN3){ref-type="table-fn"}   OR = 3.28 \[1.35, 7.97\]; *P* = 0.009[3](#T5FN3){ref-type="table-fn"}
  Konishi et al\[[@B118]\]                                                               2009       Japan         197                  Non DM, treated for HCV          DM[1](#T5FN1){ref-type="table-fn"} and HCC   Multivariate             Yes                                   HR = 4.63 \[1.677, 12.766\]; *P* = 0.003
  Hung et al\[[@B14]\]                                                                   2010       Taiwan        1470                 Treated for HCV                  DM and HCC                                   Multivariate             Yes[2](#T5FN2){ref-type="table-fn"}   HR = 4.32 \[1.23, 15.25\]; *P* = 0.023[2](#T5FN2){ref-type="table-fn"}
  Nkontchou et al\[[@B119]\]                                                             2010       France        248                  Cirrhotics                       HOMA-IR and HCC                              Multivariate             Yes                                   HR = 1.10 \[1.01, 1.21\]; *P* = 0.026
  Takahashi et al\[[@B120]\]                                                             2011       Japan         203                  Non DM, treated for HCV          DM[1](#T5FN1){ref-type="table-fn"} and HCC   Multivariate             Yes                                   HR = 6.9 \[1.7, 28.4\]; *P* \< 0.05
  Arase et al\[[@B121]\]                                                                 2013       Japan         4302                 Non treated for HCV              DM and HCC                                   Multivariate             Yes                                   HR = 1.73 \[1.3, 2.3\]; *P* \< 0.001
  Elkrief et al\[[@B45]\]                                                                2014       France        348                  Cirrhotics                       DM                                           Multivariate             Yes                                   HR = 1.938 \[1.129 , 3.328\]; *P* = 0.016
  Toyoda et al\[[@B122]\]                                                                2015       Japan         522                  Patients with SVR                DM and HCC                                   Multivariate             Yes                                   HR = 2.08 \[1.0170, 4.0133\]; *P* = 0.045
  Lai et al\[[@B123]\]                                                                   2006       Taiwan        2141                 \-                               DM and HCC                                   Multivariate             No                                    NS
  Chen et al\[[@B124]\]                                                                  2013       Taiwan        5186                 \-                               DM and HCC                                   Multivariate             No                                    NS

Association of abnormal post-challenge hyperglycaemia and HCC;

Only in SVR patients without cirrhosis;

Only in advanced liver fibrosis. HCV: Hepatitis virus infection; HCC: Hepatocellular carcinoma; SVR: Sustained virological response; HOMA-IR: Homeostasis Model Assessment of Insulin Resistance; IR: Insulin resistance; DM: Diabetes mellitus; NS: Not significant.

Five studies looked for the presence of DM/IR in HCV infected patients with HCC compared with HCV patients without HCC. Four out of five studies found a significant association between DM/IR and HCC (as compared with non-HCC) (OR from 2.0 to 11.6).

Nine out of eleven other studies found a significant association between the presence of DM/IR and the development of HCC in the follow-up of HCV infected patients (HR from 1.10 to 6.9). One study found a higher risk of HCC in diabetic patients only with SVR and without cirrhosis\[[@B14]\], while 2 others reported an increased risk of HCC only in diabetic patients with advanced fibrosis\[[@B15],[@B16]\].

DISCUSSION
==========

Many studies have evaluated the association between HCV chronic infection, insulin-resistance and diabetes mellitus. The abnormalities of carbohydrate metabolism, including hyperinsulinemia and IR, known to be *per se* related to chronic hepatic diseases, were the rationale for speculation on this relationship. Insulin-resistance is an often undetected condition, commonly coexisting with obesity and metabolic syndrome, and possibly progressing to type 2 diabetes. HCV-related type 2 diabetes mellitus may arise from a complex interaction between IR, steatosis and inflammatory processes. Epidemiologic studies supporting the association between type 2 diabetes and HCV infection were first published in the early 1990s. More recently, larger epidemiologic studies gave more in-depth analyses of the relationship between HCV chronic infection and glucose abnormalities and were included in the present analysis.

HCV infection is associated with increased rates of glucose abnormalities, including diabetes mellitus and insulin resistance
-----------------------------------------------------------------------------------------------------------------------------

In the present analysis, most studies found a significant association between HCV infection (whether active HCV RNA positive, or not *i.e*., HCV Ab positive) and diabetes mellitus or insulin resistance. This tight association was confirmed in both directions by the increased rates of HCV infection markers in DM/IR patients and the high rates of glucose abnormalities in HCV infected patients. The consistency of this association was supported by the confirmation of such results compared with different control groups, such as healthy volunteers or HBV carriers\[[@B6],[@B8],[@B12],[@B17]-[@B34]\]. The variability of HOMA-IR cut-offs used (between 1.8 and 2.5 generally) may explain the heterogeneous results reported in the literature. Confounding factors might have also led to significant bias. Indeed, some studies comparing HCV patients with healthy volunteers did not perform multivariate analysis or adjust for confounding factors. However, seven out of ten multivariate analyses found a significant increased risk of DM/IR in HCV patients (OR = 1.2-3.7), after adjusting for confounding variables such as age, gender, BMI, ethnicity and education level.

How are we able to explain the increased risk of DM in HCV infected patients? Some authors have suggested that diabetic patients might have been infected by HCV due to injections or nosocomial transmission. The association of HCV infection with IR and the widespread use of universal precautions nowadays in hospitals to avoid virus transmission probably disqualify this hypothesis. There are a variety of other possible mechanisms of increased risk of DM/IR in HCV patients. As shown in this study, glucose abnormalities in HCV patients are associated with liver fibrosis severity. Severe liver fibrosis and cirrhosis are well-known conditions that are able to induce glucose metabolism impairment. However, studies with other liver diseases, including cirrhosis, still showed an excess of risk in HCV patients compared with HBV patients\[[@B6],[@B12],[@B17],[@B31]-[@B34]\]. The ability of HCV, particularly genotype 3 viruses, to induce liver steatosis on its own, which might in turn increase the risk of DM/IR, has also been suggested in previous studies\[[@B35],[@B36]\]. Other underlying mechanisms may involve HCV *per se*. Experimental data suggest the role of inflammation. Increased HOMA-IR has been correlated with soluble Tumor Necrosis Factor Receptor1 (sTNFR1) and sTNFR2 levels\[[@B37]\]. Increased abnormal HOMA-IR was not associated with elevated serum levels of TNFα, IL6 and adiponectin in another study\[[@B38]\]. Other studies have also suggested an impairment of glucose uptake in HCV-infected patients. Glucose uptake and the surface expression of Glucose Transporters (GLUT1 and 2) were suppressed in cells infected by HCV compared with controls\[[@B39]\]. Interferon alfa restored glucose uptake, GLUT2 surface expression, mRNA expression and GLUT2 promoter activities. HCV has also been shown to impair glucose uptake and to promote IR by increasing suppressor of cytokine signalling 3 (SOC3), which inhibits insulin phosphorylation of AKT and phosphoinositide 3-kinase (PI3K)\[[@B40]\]. HCV may be involved in the regulation of phosphorylation of insulin receptor substrate 1 (ISR-1), implicated in the insulin pathway\[[@B41]\]. In HCV core transgenic mice, the viral protein was able to induce increasing TNFα levels in the liver, which in turn promoted the induction of IR. The high levels of TNFα inhibited the ISR-1, causing IR and its possible progression to diabetes. A decreased expression of ISR-1 and ISR-2 mediated by ubiquitination was observed and was inversely proportional to the liver fibrosis stage.

Interferon alfa use might lead to glucose metabolism impairment and is a potential bias. However, increased DM/IR rates have been also reported in HCV patients not taking interferon alfa\[[@B20],[@B22]-[@B25],[@B34]\]. Many studies found a decreased rate of glucose abnormalities in HCV patients who showed a SVR after interferon alfa-based therapy, and even in non virological responders in one study\[[@B42]\]. This strongly suggests a direct/indirect role of HCV on glucose metabolism impairment. As eradication of HCV seems to be effective in decreasing the occurrence rate of DM/IR, it will very be interesting to analyse the impact of new direct antiviral agents (DAAs) for preventing DM/IR and eventually cardiovascular disorders. Indeed, in a recent study, IFN-free antiviral regimen resulted in rapid changes in serum lipid profiles and intrahepatic expression of lipid-related genes in G1 patients\[[@B43]\].

Presence of glucose abnormalities in HCV infected patients, including diabetes mellitus and insulin resistance, is associated with negative liver-related outcomes
------------------------------------------------------------------------------------------------------------------------------------------------------------------

Severe liver fibrosis, the absence of SVR after interferon alfa-based treatment, and the development of HCC are the main negative outcomes of chronic HCV infection. Interestingly, the presence of DM or IR in HCV patients showed a pejorative impact on each of these end points. Most studies found an independent association of glucose abnormalities with advanced liver fibrosis, absence of SVR after antiviral treatment and HCC occurrence. Only few studies did not confirm such associations. This might be explained by the small size cohort of such studies, the heterogeneity of criteria for DM or HOMA-IR and the very high prevalence of other metabolic risk factors (such as elevated BMI) which may underestimates the impact of DM/IR. Our data is consistent with recent studies that demonstrated that DM increases cumulative incidence of decompensated cirrhosis\[[@B44]\]. In another recent survey, diabetes was independently associated with transplantation-free survival, development of ascites, renal dysfunction, bacterial infections, and HCC during the follow-up\[[@B45]\].

Experimental data suggest that increased insulin levels after hyperglycaemia leads to interferon signalling impairment. Insulin may inhibit the ability of interferon alfa to block HCV replication due to the activation of PI3K by insulin, thus leading to inhibition of STAT-1, which is involved in the interferon alfa pathway\[[@B40]\].

The impact of glucose abnormalities on virological response needs to be further evaluated with new DAA, interferon-free combinations. To date, there is very few data on the impact of GA on virological response to new DAA. Preliminary results suggest that the presence of diabetes does not appear to be predictive of treatment failure in G1 patients\[[@B46],[@B47]\]. Further studies are needed to confirm these data and to evaluate the impact of DM on SVR in patients without poor prognostic factors.

Should glucose abnormalities be corrected to increase SVR rates?
----------------------------------------------------------------

A prospective study, including 155 HCV genotype 1 patients with IR, showed no difference in SVR rates after peginterferon alfa and ribavirin were given, regardless of whether or not patients had received pioglitazone, an antidiabetic drug\[[@B48]\]. Of note, most glycemic control indexes improved significantly in the pioglitazone group except for HbA1c. Another study found higher SVR rates in G4 patients treated with pioglitazone\[[@B49]\]. Pioglitazone may alter NK cell functions and thus impair clearance of infected hepatocytes\[[@B48]\]. A retrospective cohort from Taiwan (19349 diabetic patients, 1.7% HCV positive) showed that patients taking metformin and thiazolidinediones had the lowest risk of HCC (HR 0.49 and 0.56, respectively) after adjusting for age, gender and comorbidities\[[@B50]\]. Consistently, in a prospective cohort of 100 HCV patients with ongoing cirrhosis, metformin treatment was independently associated with a decrease of HCC occurrence and liver-related death or transplantation\[[@B51]\]. In a two-year prospective follow-up of 85 patients with HCV-related HCC, HCC recurrence-free survival was increased in diabetics taking pioglitazone *vs* non-treated diabetics (44.2% *vs* 36.5%, respectively, *P* = 0.37)\[[@B52]\]. A significant decrease in HCC recurrence was observed in the pioglitazone group for patients with a BMI \> 24.

We acknowledge some limitations of this study. Although we tried to include all published studies, we may have missed others in non-English literature or data only presented at meetings. Some studies were done with a limited number of patients. For some studies included in the present analysis, it is possible that there are some remaining bias and residual confounding factors. Despite multivariate analyses, the association between glucose abnormalities improvement and improved outcome may have been influenced by unmeasured confounding factors. Such final confirmation should arise from controlled clinical trials with long-term follow-up.

In conclusion, HCV chronic infection is associated with an increased risk of DM or IR, by a likely direct effect on glucose metabolism. In such patients, DM and IR are associated with a pejorative liver-related prognosis, as shown by increased rates of severe liver fibrosis, HCC occurrence, and decreased SVR rates after interferon-based therapy. This tight relationship between DM/IR and HCV infection needs to be further analysed with new DAAs, interferon-free combinations, with special attention to improvement in glucose abnormalities and long-term follow-up.
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